TCERG1 and myeloid sarcoma: After ROC analysis both antigens show really high sensitivity, specificity and LR+ value (DDX24 72.22%, 78.95%, 3.43; TCERG1 100%, 89.47%, 9.5) and although further independent validations are needed, the data indicates a promising use of the two antigens as biomarker to discriminate MS from OND.